Current Headlines

  1. Ben-Gurion University Introduces Novel AI Platform For Monitoring And Predicting ALS Progression
    2/19/2019

    BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), disclosed today a novel artificial intelligence (AI) platform for monitoring and predicting the progression of neurodegenerative diseases for the purpose of identifying markers for personalized patient care and improved drug development

  2. Biohaven's Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy
    2/19/2019

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that it received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its product candidate verdiperstat (previously BHV-3241), a novel myeloperoxidase (MPO) inhibitor, for the treatment of multiple system atrophy (MSA)

  3. Light-Based Production Of Drug-Discovery Molecules
    2/18/2019

    EPFL chemists have developed a light-based method for cheap and simple production of chemical molecules used in drug discovery, such as muscle relaxants and antimicrobials

  4. SK Biopharmaceuticals And Arvelle Therapeutics Announce Agreement To Develop And Commercialize Cenobamate In Europe
    2/14/2019

    Gyeonggi-do, South Korea /PRNewswire/ - SK Biopharmaceuticals and Arvelle Therapeutics GmbH today announced that they have entered into an exclusive licensing agreement for Arvelle to develop and commercialize cenobamate in Europe

  5. Tanabe Research Labs Announce FDA Acceptance Of Its IND Application For TR1801-ADC (MT-8633), An ADC Targeting cMet Positive Solid Tumors
    2/14/2019

    Tanabe Research Laboratories U.S.A. Inc. (TRL), a subsidiary of Mitsubishi Tanabe Pharmaceutical Corporation, is a California based research, development and clinical stage company specializing in antibody technologies to treat cancer and other diseases with unmet medical needs

  6. Novartis Receives FDA Approval For Egaten® For The Treatment Of Fascioliasis, A Neglected Tropical Disease
    2/13/2019

    Novartis announced today that the US Food and Drug Administration (FDA) has approved Egaten® (triclabendazole) for the treatment of fascioliasis in patients six years of age and older

  7. Jubilant Biosys Expands Collaboration With Sanofi In CNS Therapeutic Area
    2/13/2019

    Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, today announced a new integrated drug discovery collaboration with Sanofi in the CNS therapeutic area

  8. Exelixis To Initiate Phase 1 Clinical Development Of XL092, First New Compound To Enter The Clinic From Reinitiated Discovery Efforts
    2/12/2019

    Exelixis, Inc. recently announced it is initiating phase 1 clinical development for XL092, the first internally-discovered Exelixis compound to enter the clinic following the company’s reinitiation of drug discovery activities

  9. Single-Use Technology For Biologics Manufacturing In St. Louis, Missouri
    2/12/2019

    Watch this video and learn about Thermo Fisher Scientific’s expansion of its biologics site in St. Louis, Missouri. The facility will be the single largest single-use technology CDMO in North America. 

  10. Thermo Fisher Receives Commercial Licenses for Two Biologic Therapies
    2/12/2019

    In 2018, the Pharma Services biologics business within Thermo Fisher Scientific, supported the commercialization of two new therapeutics for its clients. The St. Louis, Missouri and the Groningen, Netherlands sites both completed FDA Pre-Approval Inspections (PAIs) and received Establishment Inspection Reports (EIRs) for the commercial manufacture of biologic therapies.